Skip to main content
Equibles

ADAR1 Capital Management, LLC

Position in VTGN — Vistagen Therapeutics, Inc.

CIK 1940272 AUSTIN, TX
Back to VTGN Full portfolio

Position in VTGN

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$80,762
-$347,388 QoQ
Shares Held
351,141
-53.3% QoQ
Ownership
0.791%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#10
of 48 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in VTGN Over Time

Shares Held

Position Value (USD)

Derivatives in VTGN

reported options exposure · as of Dec 31, 2025
CallValue
$0
CallShares
0
PutValue
$79,200
PutShares
120,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ADAR1 Capital Management, LLC holds $1,760,528,411 across 192 Biotechnology names. VTGN ranks #182 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ABVX
Abivax S.A.
 1,804,703 $240,494,721
2 PTGX
Protagonist Therapeutics, Inc
 960,863 $117,782,586
3 ROIV
Roivant Sciences Ltd.
 3,157,008 $111,726,513
4 IMVT
Immunovant, Inc.
 2,330,716 $89,802,487
5 ZLAB
Zai Lab Ltd
 3,369,034 $64,011,646
6 AGIO
Agios Pharmaceuticals, Inc.
 1,288,053 $47,799,646
7 CRNX
Crinetics Pharmaceuticals, Inc.
 1,222,080 $45,730,233
8 CYTK
Cytokinetics Inc
 457,907 $39,009,097

All Filings in VTGN

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $80,762 351,141
2026-03-31 $428,150 751,141
2025-12-31 $411,559 623,575
2025-12-31 $79,200 120,000
2025-09-30 $401,370 113,062
2025-06-30 $841,530 420,765
2025-03-31 $1,051,912 420,765
2024-12-31 $358,309 121,461
2024-09-30 $490,864 163,078
2024-03-31 $474,872 89,938
2023-12-31 $1,261,880 245,502